Cardiovascular In Vitro & Ex Vivo Platforms

Cardiovascular in vitro and ex vivo platforms address critical gaps in target validation, lead compound prioritization, safety pharmacology, and mechanism‑of‑action studies—all while reducing reliance on whole‑animal testing. These systems afford precise control over experimental variables, enabling high‑throughput screening of drug candidates, quantitative assessment of functional endpoints, and mechanistic dissection of signaling cascades.